BioCentury | Aug 20, 2020
Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

...Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells  By lauren martz, senior...
...a drug with a convenient route of administration during the pandemic. FDA approved the once-monthly, auto-injectable anti-CD20...
...uphill battle in the crowded MS marketplace. Other B cell-depleting drugs are available including blockbuster CD20...
BioCentury | Aug 17, 2020
Deals

Via $3.4B Principia takeout, Sanofi can explore potential of Btk inhibitor beyond MS

...has disease progression benefits over other oral MS drugs and relapse reduction in line with CD20...
BioCentury | Jul 17, 2020
Emerging Company Profile

Acepodia: linking antitumor antibodies to immune cells

...granted JW Therapeutics (Shanghai) Co. Ltd. development and commercialization rights to ACE1702 and ACE1655, an anti-CD20...
BioCentury | Jul 11, 2020
Translation in Brief

Peptide blocker of myeloid checkpoint; plus a magnet-based device to collect circulating tumor cells, severe vs. mild COVID-19 immune cell profiles and more

...model of melanoma enhanced an anti-TYRP1 antibody-mediated reduction in lung metastases. Combining the peptide with anti-CD20...
BioCentury | Jun 22, 2020
Finance

First-day pop gives SinocellTech massive market cap on Shanghai’s STAR

...has submitted NDAs for SCT800, a recombinant Factor VIII for hemophilia A, and SCT400, an anti-CD20...
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...are in Phase I testing for hematological malignancies. Epcoritamab targets CD3 on T cells and CD20...
BioCentury | Jun 10, 2020
Deals

Deals for leading Chinese immuno-oncology companies: Innovent lands Roche as partner; JW raises $100M

...lymphoma (NHL) patients in the Phase I/II NP30179 trial of CD20-TCB. The therapy has two anti-CD20...
BioCentury | Jun 4, 2020
Product Development

With impending Benlysta submission, GSK seeking new paradigm in lupus nephritis treatment

...Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) is starting a Phase III trial this year of CD20-targeting...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

...While Novartis had said in February that FDA and EMA were reviewing applications for the anti-CD20...
BioCentury | Jun 2, 2020
Finance

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

...testing: anti-HER2 mAb GB221 for metastatic breast cancer, infliximab biosimilar GB242 for rheumatoid arthritis and anti-CD20...
...64% stake in Genor. Hu said Walvax is no longer a majority stake holder. Targets CD20...
...factor α Hongjiang Li, Staff Writer Biosimilar trastuzumab (GB221) Biosimilar infliximab (GB242) Biosimilar rituximab (GB241) genolimzumab (APL-501, GB226) Genor Biopharma Co. Ltd. CD20 Epidermal...
Items per page:
1 - 10 of 1414